Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of apatinib mesylate plus oral etoposide versus weekly paclitaxel in platinum-failed recurrent ovarian cancer
CTR20191305Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib, etoposide, paclitaxel in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui Therapeutics. Started Aug 2019; status: active.
02
Drugs
Rivoceranibetoposidepaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20191305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191305.